Activity of IQG-607, a new orally active compound in a murine model of Mycobacterium tuberculosis infection

@article{Santos2014ActivityOI,
  title={Activity of IQG-607, a new orally active compound in a murine model of Mycobacterium tuberculosis infection},
  author={Di{\'o}genes Santiago Santos},
  journal={BMC Proceedings},
  year={2014},
  volume={8},
  pages={O8 - O8}
}
  • D. Santos
  • Published 1 October 2014
  • Biology, Medicine
  • BMC Proceedings
Tuberculosis (TB) caused by Mycobacterium tuberculosis, remains a major global health concern. According to the World Health Organization (WHO), TB was responsible for the occurrence of 1.8 million deaths in 2012 [1], and currently represents the main cause of human death due to a single pathogen. Increasing HIV-TB co-infections, the emergence of multidrug-resistant (MDR) [2,3], extensively drug-resistant(XDR) [3,4], and, more recently, of totally drug resistant strains (TDR) [5] have increased… 
Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.

References

SHOWING 1-9 OF 9 REFERENCES
The challenge of new drug discovery for tuberculosis
TLDR
In this review, innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients are discussed.
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
TLDR
The main focus of the contribution is on new data describing the rationale for the design of a pentacyano(isoniazid)ferrateII compound that requires no KatG-activation, its chemical characterization, in vitro activity studies against WT and INH-resistant I21V M. tuberculosis enoyl reductases, the slow-onset inhibition mechanism of WT InhA by the inorganic complex, and molecular modeling of its interaction with WT InHA.
Advances in the development of new tuberculosis drugs and treatment regimens
TLDR
Current concepts and recent advances in TB drug discovery and development are covered, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid
TLDR
Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis and was sufficient to confer clinically relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis.
An inorganic complex that inhibits Mycobacterium tuberculosis enoyl reductase as a prototype of a new class of chemotherapeutic agents to treat tuberculosis
TLDR
In conclusion, IQG607 represents a promising chemotherapeutic agent aiming at the inhibition of a validated and druggable molecular target.
An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
The in vitro kinetics of inactivation of both wild-type and I21V InhA enzymes by [FeII(CN)5(INH)]3- indicate that this process requires no activation by KatG, and no need for the presence of NADH.